| AstraZeneca to Evaluate Orexo Respiratory Programme Previously Partnered with Janssen |
Abstract
|
|
Heather Cartwright |
|
| Lycera and Merck & Co. Form Second Autoimmune Disease Collaboration |
Abstract
|
|
Heather Cartwright |
|
| Merck & Co. Changes Tack on Biosimilars with Samsung Bioepis Collaboration |
Abstract
|
|
Heather Cartwright |
|
| Avalon Ventures’ Afraxis Licenses Entire Drug Portfolio to Genentech |
Abstract
|
|
Heather Cartwright |
|
| The Medicines Company Licenses Alnylam’s RNAi Programme Targeting PCSK9 |
Abstract
|
|
Heather Cartwright |
|
| Opexa Therapeutics Grants Merck Serono Option to Multiple Sclerosis T-cell Therapy |
Abstract
|
|
Heather Cartwright |
|
| Reckitt Benckiser Licenses Seven OTC Brands from BMS in Latin America |
Abstract
|
|
Heather Cartwright |
|
| Biocon Finds a New Partner for its Biosimilar Insulin Analogues in Mylan |
Abstract
|
|
Heather Cartwright |
|
| Roche Licenses Chiasma’s Late-Stage Oral Acromegaly Therapy |
Abstract
|
|
Heather Cartwright |
|
| Baxter Buys Late-Stage Haemophilia Drug OBI-1 from Ipsen and Troubled Inspiration Biopharmaceuticals |
Abstract
|
|
Heather Cartwright |
|
| Actavis Expands in Women’s Health with Uteron Pharma Purchase |
Abstract
|
|
Heather Cartwright |
|
| Biogen Idec Buys Complete Ownership of Tysabri® from Elan |
Abstract
|
|
Heather Cartwright |
|
| Eisai Divests US Rights to CTCL Therapy Targretin® to Valeant |
Abstract
|
|
Heather Cartwright |
|
| A Review of Deal Making in 2012 |
Abstract
|
|
Heather Cartwright |
|
